Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Breast tumor tissue microarrays were evaluated for PD-L1 expression, which was present in 19% (20 of 105) of TNBC specimens. 24764583 2014
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer. 26317899 2015
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 GeneticVariation disease BEFREE Recently, recurrent copy number gains (CNG) in chromosome 9p involving PD-L1 were detected in many cancer types including lung cancer, melanoma, bladder cancer, head and neck cancer, cervical cancer, soft tissue sarcoma, prostate cancer, gastric cancer, ovarian cancer, and triple-negative breast cancer. 29212506 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. 28230773 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE These results demonstrate that PIPKIγ-dependent expression of PD-L1 is likely important for the progression of triple negative breast cancer. 28465490 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE In clinical cases, we observed that the expression of ERO1-α in triple negative breast cancer was related to the expression of PD-L1. 28160557 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE The anti-PD-L1 drug atezolizumab produced durable responses among 10% of patients with triple-negative breast cancer in a large phase I trial presented at the American Association for Cancer Research Annual Meeting 2017. 28377497 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Our findings suggest that PD-L1-positive/TILs-low tumors are associated with a poor prognosis in patients with TNBC, and that it is important to focus on the combination of PD-L1 expression on tumor cells and TILs present in the tumor microenvironment. 28107186 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE PERK-Phosphorylated eIF2α Pathway Suppresses Tumor Metastasis Through Downregulating Expression of Programmed Death Ligand 1 and CXCL5 in Triple-Negative Breast Cancer. 29053414 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Higher PD-L1 expression in tumor cell was related to larger tumor size, estrogen receptor negativity, progesterone receptor negativity, human epidermal growth factor type-2 positivity, and triple-negative breast cancer. 29041905 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Our study found that high levels of PD-L1 could be expressed in TNBC, which was correlated with the prevalence of TILs. 29104508 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE The findings of these studies appear to support the potential of immune checkpoint inhibitors targeting the PD-1/PD-L1 axis in triple negative breast cancer. 28936553 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE However in the multivariate analysis only PD-L1 expression on tumor cells remained significantly associated with pCR (OR = 1,13; 95% CI 1,01-1,27), suggesting that the expression of this biomarker could be associated with a subpopulation of TNBC more likely to respond to chemotherapy. 29387716 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE In addition, PDL1 and LDHA acted as ceRNAs to promote the expression and function of each other through regulation of miR-34a in TNBC. 28915924 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE The pooled odds ratios (ORs) indicated that PD-L1 expression was associated with positive lymph node metastasis, higher histological grades, estrogen receptor (ER)-negativity, and triple-negative breast cancer (TNBC). 28430626 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Poly(I:C) treatment induced PD-L1 expression on TNBC cells, and combined poly(I:C) and anti-PD-1 treatment prolonged metastasis-free survival in a neoadjuvant setting via the induction of a tumor-specific T-cell response. 28848054 2017
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE In this review, we discuss the current evidence for PD-1/PD-L1 blockade in metastatic triple-negative breast cancer (TNBC), HER2+ breast cancer and ER+ disease, as well as the emerging evidence for use in the early-stage (neoadjuvant) setting. 29808015 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE The obtained overall response rate of PD-1/PD-L1 monotherapy varied from 5 to 30% in heavily pretreated triple negative breast cancer (TNBC). 29287242 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE The correlation between syntenin1 and PD-L1 was further confirmed using tumour tissues derived from patients with TNBC (r = 0.509, P < 0.001). 29845474 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Anthracycline and taxane up-regulated PD-L1 and Gal-9 expression in some subtypes of TNBC. 30139555 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE These data suggest that the JAK2/STAT1 pathway in TNBC might regulate the dynamic expression of PD-L1 that is induced in the setting of an inflammatory response. 29933930 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE These data suggest that a minimal system comprised of cGAMP-NP alone is sufficient to modulate the tumor microenvironment to effectively control PD-L1-insensitive TNBC. 30429378 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Together, our results provide a strong rationale for investigating the targeting of PD-L1 glycosylation in TNBC further. 30323975 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 AlteredExpression disease BEFREE Univariate analysis showed that PD-1 and PD-L1 expressions also significantly shortened disease free survival in TNBC (p = 0.048, HR = 3.318) (p = 0.007, HR = 8.375). 29615063 2018
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.100 Biomarker disease BEFREE Furthermore, we found that targeting both MHC-I and II restricted tumor epitopes was necessary to decrease the growth of the poorly immunogenic TNBC model 4T1 and that combination with PD-L1 blockade increased the number of responders to checkpoint inhibition. 30221051 2018